Health Career Pathways
How I became an Emergency Physician
with Dr Kim Hansen
Dr Kim Hansen was initially attracted to emergency medicine because of its dynamic and chaotic environment. She enjoyed organising the chaos of the emergency department and working with a variety of patients, from newborn babies to centenarians. Dr Hansen found it fulfilling to help people get better or provide them with assistance and guidance when they couldn’t be cured. The unpredictability of the work was also part of the appeal, and she dedicated herself to developing the skills required to be a good emergency doctor.
To prepare for this role, the Dr Hansen worked in various specialties, including intensive care, paediatrics, anaesthesiology, general medicine, and infectious diseases. She also served as a board member and Chair for the Emergency Medicine Foundation and contributed to the Australasian College for Emergency Medicine in numerous ways, such as advancing women in emergency medicine and promoting patient safety and quality.
Dr Hansen acknowledges that emergency medicine can be a challenging field, as it involves shift work and can be emotionally taxing. However, she remains passionate about what she does to continue to contribute to her department, hospital, and the broader field of emergency medicine. Dr Hansen encourages medical students and junior doctors who enjoy working in a fast-paced, unpredictable environment to consider emergency medicine as a career.
Reflecting on her experience and career pathway, emergency medicine offers a broad range of opportunities, from working in a hospital emergency department to pre-hospital care, retrieval coordination, virtual healthcare, and other specialties such as intensive care, palliative care, or sports medicine. Dr Hansen sees emergency physicians as a cohesive group who support each other and enjoy each other’s company, and the field offers great mobility and work-life balance.
You Might also like
-
New Generative AI and machine learning frontier on unused patient care data
Drawing from GE’s 125-year legacy in healthcare, Amit Yadav, CEO GE HealthCare ANZ is leading efforts to integrate AI into medical imaging devices and optimise workflow efficiencies. He stresses the importance of leveraging the vast amount of untapped healthcare data, with an emphasis on automating manual processes to enhance productivity. Additionally, his focus extends to utilising AI for workflow optimisation and ensuring compliance with local regulations and standards to prioritise safety.
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
-
Using human skin hair follicles to treat Alzheimer’s disease
Professor Michael Valenzuela is a science opinion leader, innovator and creative thinker with a career-long commitment to the prevention and treatment of dementia.
Following that he completed graduate medicine and medical training at the Prince of Wales Hospital. In 2012, he established the Regenerative Neuroscience Group at the University of Sydney, and in 2017 became the university’s first Professor of Regenerative Medicine.
Professor Valenzuela’s group discovered a new cell type with potential for regenerative medicine, a rare neural precursor cell found deep within the human hair follicle. He is the main inventor on several related patents and is the Founder and Chief Scientific Officer of Skin2Neuron – a biotech company developing the first neurorestorative cell therapy for Alzheimer’s disease based on this work.